Dolutegravir Plus Lamivudine Simplified Therapy

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2030

Conditions
HIV/AIDS
Interventions
DRUG

DTG+ 3TC

It is a simplified therapy regimen study of dolutegravir combined with lamivudine for HIV-1 infected patients in the real world of China.

Trial Locations (1)

510060

RECRUITING

Guangzhou 8th People's Hospital, Guangzhou

All Listed Sponsors
collaborator

Shenzhen Third People's Hospital

OTHER

collaborator

Dongguan People's Hospital

OTHER_GOV

collaborator

Fifth Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

The Third People's Hospital of Guilin

UNKNOWN

collaborator

Guangxi Longtan hospital

UNKNOWN

collaborator

The Fourth People's Hospital of Nanning

OTHER

collaborator

The Third People's Hospital of Kunming

UNKNOWN

collaborator

Yunnan AIDS Care Center

OTHER

collaborator

Meng Chao Hepatobiliary Hospital of Fujian Medical University

OTHER

collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

lead

Guangzhou 8th People's Hospital

OTHER